Introduction {#Sec1}
============

LDL-C has been recognized as most important risk factor for coronary artery disease (CAD) for more than 30 years \[[@CR1]\]. In particular, statin trials established a clear link between therapeutic lowering of low-density lipoprotein cholesterol (LDL-C) and reduced incidence of cardiovascular event rates \[[@CR2], [@CR3]\]. In recent years, the equally atherogenic, thrombogenic, and inflammatory potential of lipoprotein(a) (Lp(a)), which was first identified by K. Berg in 1963, has gained increasing attention \[[@CR4]--[@CR9]\]. After withdrawal of nicotinic acid in Europe in January 2013, there is no pharmacological treatment available to lower an elevated Lp(a) level significantly. Unlike with hypercholesterolemia, it was unclear for a long time whether Lp(a) level reduction would improve cardiovascular outcome.

Lipoprotein apheresis (LA) treatment can effectively lower LDL-C as well as Lp(a) by 60--80 % during a single treatment session. After encouraging experiences in individual patients with isolated Lp(a) hyperlipoproteinemia (Lp(a)-HLP), results of LA treatment were published for this new indication in a multicenter, longitudinal cohort study with 120 patients \[[@CR10]\]. Reduction of the Lp(a) level by LA treatment resulted in a decline of the per-year and per-patient major adverse cardiac event (MACE) count from 1.06 to 0.14, representing a reduction of 86 %. Due to methodological weaknesses in this study and considering costs of LA reimbursement, a prospective study was stipulated by German authorities. A randomized design of the study, which was initially suggested, was rejected by ethics committees in view of the favorable results of the retrospective study. In the multicenter study "Pro(a)LiFe," 170 patients were included after approval for chronic LA due to isolated Lp(a)-HLP according to the German reimbursement authority Federal Joint Committee (GBA) \[[@CR11]\]. Observation periods of 2 years before and 2 years after commencing LA treatment demonstrated decline of the annual per-patient MACE rate from 0.41 ± 0.45 to 0.09 ± 0.22 meaning a significant reduction of 78 %. Overall, this prospective study fully confirmed results of the earlier retrospective study.

A monocentric, retrospective, longitudinal cohort study was conducted at our medical competence center for apheresis, performing nearly 6000 LA treatments per year. All investigated patients had been approved for chronic LA treatment according to the guidelines of GBA, following an initial and annually renewable application, due to the following diagnoses: severe hypercholesterolemia or isolated Lp(a)-HLP with progressive CVD \[[@CR12]\]. Complete details of this study have been published elsewhere \[[@CR13]\].

Results {#Sec2}
=======

Patient characteristics {#Sec3}
-----------------------

The study included 118 consecutive patients who received chronic LA treatment between October 1996 and December 2013 at our center for a mean individual period of 6.8 ± 4.9 (range, 1--23) years. This amounted to a total of 797 treatment years including 36,745 single treatment sessions. Patient characteristics are summarized in Table [1](#Tab1){ref-type="table"}. Indication for LA treatment included severe hypercholesterolemia in approximately 70 % and isolated Lp(a)-HLP of \> 60 mg/dL with progressive CVD in approximately 30 %. To fulfill the reimbursement criteria of isolated Lp(a)-HLP, LDL-C levels were treated by maximally tolerated lipid-lowering medication to reach the target level of \< 100 mg/dL as part of optimized control of all other cardiovascular risk factors. Irrespective of the criteria for LA indication, there was a substantial overlap between the two dyslipidemia types in the 118 patients: 111 had hypercholesterolemia requiring lipid-lowering medication (94.1 %) and 83 patients had Lp(a)-HLP (70.3 %).Table 1Baseline characteristics at the time of first lipoprotein apheresis treatmentAll patients (*n* = 118)Male/female77 (65.3 %)/41 (34.7 %)Age, years59.6 ± 11.2 (range, 25--83)Male, years58.1 ± 10.5 (range, 37--81)Female, years62.5 ± 11.9 (range, 25--83)Body mass index, kg/m^2^27.7 ± 4.2Cardiovascular risk factors  Positive family history79 (67.0 %)  Hypercholesterolemia111(94.1 %)  Lp(a) hyperlipoproteinemia83 (70.3 %)  Arterial hypertension72 (61.0 %)  Diabetes mellitus28 (23.7 %)Smoking habits  Never69 (58.5 %)  Former47 (39.8 %)  Current2 (1.7 %)Chronic renal failure as assessed by Cockcroft--Gault formula: eGFR, mL/min  30--5918 (15.3 %)  15--292 (1.7 %)\< 15 or dialysis7 (5.9 %)Cardiovascular diseases  Coronary artery disease (CAD)118 (100 %)    One-vessel CAD16 (13.5 %)    Two-vessel CAD18 (15.3 %)    Three-vessel CAD84 (71.2 %)  Cerebrovascular disease94 (79.7 %)  Peripheral artery disease27 (22.9 %)Indication for LA Severe hypercholesterolemia83 (70.3 %)    Treatment failure10 (12.0 %)    Intolerability of medical treatment73 (88.0 %) Isolated Lp(a) elevation35 (29.7 %)Time between first cardiovascular event and first LA, years6.4 ± 5.6 (range, 1--27)

79.3 % of nonhemodialysis patients were treated via peripheral venous access, whereas 20.7 % required an AV shunt. The average interval between treatments was 1 week resulting in a mean of 51.3 treatments per patient per year. Use of different LA methods and treatment volumes of plasma and blood are summarized in Table [2](#Tab2){ref-type="table"}.Table 2Lipoprotein apheresis (LA) methods and treated plasma and blood volumesLA methodNumber of treatments (*n* = 36,745)Plasma (P) and blood (B) volumes, mL per treatmentHeparin-induced extracorporeal LDL precipitation apheresis17,758 (48.3 %)3103 ± 705 (P)Temperature optimized Double filtration plasmapheresis9370 (25.5 %)3100 ± 675 (P)Polyacrylate adsorption (Direct adsorption of lipoproteins from whole blood)9218 (25.1 %)8129 ± 1,173 (B)Simple DFPP (Membrane filtration optimised novel extracorporeal treatment)399 (1.1 %)3600 ± 842 (P)

Medication and laboratory parameters {#Sec4}
------------------------------------

All patients were receiving maximally tolerated lipid-lowering medication and individually optimized cardiac medication prior to and during each stage of LA treatment. Notably, these included platelet aggregation inhibitors, beta blockers, ACE inhibitors, and angiotensin receptor blockers as well as diuretics. The contraindication of ACE inhibitors with extracorporeal adsorption techniques had to be considered.

Laboratory parameters before and during chronic LA treatments are summarized in Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}. The mean interval value C~mean~ between two LA treatments was calculated according to the formula suggested by Kroon \[[@CR14]\]: C~interval\ mean~ = C~min~ + 0.73 (C~max~ − C~min~), where C~min~ corresponds to the minimal LDL-C or Lp(a) concentrations right after LA treatment and C~max~ expresses the LDL-C or Lp(a) concentrations immediately before the next LA treatment \[[@CR14]\]. Patients with the indication of severe hypercholesterolemia also exhibited elevated Lp(a) levels with an average of 75.0 mg/dL in 57.8 % (48 of 83) patients. The upper average limit could be lowered simultaneously with that of LDL-C, with equal efficacy per session but by 56.4 % regarding average levels of long-term treatment. So the long-term Lp(a) reduction was substantially higher compared with LDL-C reduction by only 32.1 %. In the patient group with isolated Lp(a) elevation, average levels of Lp(a) could be reduced by 52,8 %, whereas LDL-C was only lowered by 22,7 % (Table [4](#Tab4){ref-type="table"}).Table 3Plasma concentrations of low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp(a)) in patients with severe hypercholesterolemia before, in first month, and during steady state of chronic lipoprotein apheresis (LA)*LDL-CBefore LAFirst monthSteady stateMean total LDL-C reduction (%)*C~max~ before LA (mg/dL)Not done154.7 ± 51.4148.8 ± 43.9C~min~ after LA (mg/dL)Not done63.1 ± 26.848.9 ± 18.6Reduction by LA (%)Not done58.7 ± 12.066.7 ± 10.8\
(*p \<*\
 0.0001)Interval mean level (mg/dL)176.4 ± 67.0128.1 ± 42.6119.8 ± 34.732.1 ± 19.6\
(*p \<*\
 0.0001)*Lp(a)Before LAFirst monthSteady stateMean total Lp(a) reduction (%)*C~max~ before LA (mg/dL)Not done52.5 ± 55.440.2 ± 38.9C~min~ after LA (mg/dL)Not done23.4 ± 25.214.0 ± 12.6Reduction by LA (%)Not done54.6 ± 20.765.2 ± 30.7\
(*p \<*\
 0.0001)Interval mean level (mg/dL)75.0 ± 64.548.3 ± 47.232.7 ± 31.056.4 ± 20.5\
(*p \<*\
 0.0001)There have been patients in whom no Lp(a) was detectable, but they have not been separately recordedTable 4Plasma concentrations of lipoprotein(a) (Lp(a)) and low-density lipoprotein cholesterol (LDL-C) in patients with isolated Lp(a) elevation before, in first month, and during steady state of chronic lipoprotein apheresis (LA)*Lp(a)Before LAFirst monthSteady stateMean total Lp(a) reduction (%)*C~max~ before LA (mg/dL)Not done97.2 ± 56.074.5 ± 24.3C~min~ after LA (mg/dL)Not done39.6 ± 23.124.5 ± 8.9Reduction by LA (%)Not done59.5 ± 11.966.8 ± 5.8\
(*p \<*\
 0.0001)Interval mean level (mg/dL)127.2 ± 67.381.2 ± 45.860.0 ± 19.552.8 ± 23.0\
(*p \<*\
 0.0001)*LDL-CBefore LAFirst monthSteady stateMean total LDL-C reduction (%)*C~max~ before LA (mg/dL)Not done92.6 ± 33.991.7 ± 27.9C~min~ after LA (mg/dL)Not done41.0 ± 18.231.8 ± 15.6Reduction by LA (%)Not done55.3 ± 12.965.7 ± 8.7\
(*p \<*\
 0.0001)Interval mean level (mg/dL)96.1 ± 33.577.7 ± 28.174.3 ± 23.722.7 ± 31.2\
(*p \<*\
 0.0001)

Analysis of events {#Sec5}
------------------

Analysis of events was performed for 118 patients who were observed for an average of 6.4 ± 5.6 (range, 1--27) years between their first cardiovascular event and the beginning of LA treatment and were then observed for an average of 6.8 ± 4.9 (range, 1--23) years during chronic LA treatment. In accord with other authors' definitions \[[@CR10], [@CR11]\], cardiac death, a non-lethal myocardial infarction (MI), coronary bypass surgery (CABG), and percutaneous coronary intervention or stent implantation (PCI) all counted as MACEs representing the primary composite outcome parameter. Adverse cardiac and vascular events (ACVEs) made up the secondary composite outcome parameter, meaning all coronary as well as vascular events in all noncardiac vascular regions. The absolute number of cardiovascular events (MACEs and ACVEs) preceding and following initiation of chronic LA treatment and derived reduction rates for all investigated patients and for the patients of both treatment indications are shown in Table [5](#Tab5){ref-type="table"}. During this period, the average annual MACE rate per patient could be reduced from 0.35 to 0.07 in the total of 118 patients. The average reduction rate after initiation of LA treatment was 79.7 % for MACEs and 73.3 % for ACVEs.Table 5Total number of major adverse coronary events (MACEs) and adverse cardiac and vascular events (ACVEs) in 6.4 ± 5.6 (range, 1--27) years before and 6.8 ± 4.9 (range, 1--23) years after commencing chronic lipoprotein apheresis (LA)*All patients (n = 118)*Before LA (*n*)During LA (*n*)Reduction rate (%)MACE2615379.7 (*p* \< 0.0001)Myocardial infarction681085.3 (*p* \< 0.0001)Percutaneous coronary intervention1383773.2 (*p* \< 0.0001)Coronary artery bypass graft55689.1 (*p* \< 0.0001)ACVE2897773.3 (*p* \< 0.0001)*Patients with severe hypercholesterolemia (n = 83)*MACE1674473.7 (*p* \< 0.0001)Myocardial infarction48883.3 (*p* \< 0.0001)Percutaneous coronary intervention81 3161.7 (*p* \< 0.0001)Coronary artery bypass graft38586.8 (*p* \< 0.0001)ACVE1846664.1 (*p* \< 0.0001)*Patients with isolated Lp(a) elevation (n = 35)*MACE94990.4 (*p* \< 0.0001)Myocardial infarction20290.0 (*p* \< 0.0001)Percutaneous coronary intervention57689.5 (*p* \< 0.0001)Coronary artery bypass graft17194.1 (*p* \< 0.0001)ACVE1051189.5 (*p* \< 0.0001)

Figure [1](#Fig1){ref-type="fig"} shows the number of annual MACE rates with related numbers of patients before and during LA treatment, i.e., MACE rate per patient per year. The number of analyzed patients varied in years during LA treatment due to the retrospective design. The MACE rate increased continuously prior to LA treatment from 0.04 in year − 6 to 0.9 in year − 1. Once LA treatment began, this declined from 0.15 in year + 1 to 0.02 in year + 6. Comparing corresponding years before and during LA treatment within a 12-year period (year − 6 to year + 6), all pairs exhibited a MACE reduction being essentially identical to the mean reduction calculated with all events for the entire observation period.Fig. 1Major adverse coronary event (MACE) rates per year in relation to the number of observed patients and in relation to the chosen time interval. All patients (*n* = 118) with severe hypercholesterolemia (*n* = 83) and isolated lipoprotein(a) (Lp(a)) elevation (*n* = 35) are included in this figure (LA lipoprotein apheresis)

Safety and tolerability of LA treatment {#Sec6}
---------------------------------------

During 36,745 LA treatments, there were unexpected adverse events in 1.1 %, vascular problems in 2.1 %, and technical problems in 0.08 % of cases (for details, see \[[@CR13]\]). Overall, 99.5 % of all treatments reached their treatment target, defined by the plasma or blood volume intended to treat.

Termination of chronic LA treatment {#Sec7}
-----------------------------------

LA treatment was terminated during the observation period for 27 of the total 118 patients. Reasons for termination are summarized in Table [6](#Tab6){ref-type="table"}. Chronic LA treatment was halted in four patients at their request, resulting in treatment adherence rate of 99.5 % per year.Table 6Reason for terminating chronic lipoprotein apheresis (LA) in the cohort of 118 patients covering 797 patient yearsReasonNumber of patients terminating LARelation to total number of patient yearsTotal27Death151 per 53 patient years Dialysis patients61 per 4 patient years Non-dialysis patients91 per 86 patient years Cardiac death71 per 114 patient years (8,8% per 10 patient years)Progressive malignant disease6Change of patient's residence2Patient's will41 per 200 years

Discussion {#Sec8}
==========

In this retrospective study, 118 patients with established indication for lipoprotein apheresis due to HLP with high CVD risk were analyzed, who received more than 36,000 LA treatment sessions for an average time period of nearly 7 years. LA demonstrated to be an effective, safe, and well-tolerated extracorporeal treatment. Immediate effect of LA was lowering of both LDL-C and Lp(a) levels by an average of 67 %, irrespective of the initial level. Regarding time-averaged levels in the long-term, LA showed significantly less LDL-C reduction of 32 % in patients with severe hypercholesterolemia compared with 53 % long-term Lp(a) reduction in patients with isolated Lp(a)-HLP. The patients who started Lp(a) apheresis treatment with an already low LDL-C level of 96 mg/dL had an even faster LDL-C rebound and a correspondingly smaller long-term reduction rate of only 23 %. A similar observation of 18 % long-term LDL-C reduction was noted in the Pro(a)LiFe study \[[@CR11]\]. In accord with Jaeger et al. \[[@CR10]\], who reported a 36 % long-term Lp(a) reduction, but in contrast to our own findings (53 %), authors of this study also noted a lower long-term Lp(a) reduction of 32 %. In all three investigated populations, lowering of MACE rates after commencing extracorporeal Lp(a) elimination was equally impressive, i.e., by 78 % \[[@CR11]\], by 86 % \[[@CR10]\], and by 90 %, respectively.

Approximately 70 % of LA patients across Germany are treated due to severe hypercholesterolemia and 30 % due to isolated Lp(a)-HLP \[[@CR15]\], which fully matches our patient population in proportion. The initial risk for our patients with high LDL-C levels was markedly lower (0.65) in the year prior to LA treatment than for Lp(a) patients (1.49). MACE reduction with LA treatment was lower in LDL-C patients (73.7 %) than in the Lp(a) group (90.4 %). This appears to confirm the conclusion that the higher the initial risk, the greater the effect of LA treatment. This relationship has already been observed between statin therapy and hypercholesterolemia leading to the number needed to treat. In the Pro(a)LiFe patient population, only three patients needed LA treatment for 1 year to avoid a MACE \[[@CR11]\], which matches our findings.

In addition to the lipoprotein-eliminating effect of LA, a number of pleiotropic, especially pro-rheological and anti-inflammatory effects, must be mentioned \[[@CR16]\]. It could be hypothesized that also the pulsatile fall in lipoproteins to extremely low values immediately after LA treatment might have a sustained positive effect on the vascular endothelium, resulting in a reduction of cardiovascular events more than double as high as expected from LDL-C elimination by statins alone \[[@CR2], [@CR17]\].

The clinical efficacy of LA can also be discussed in terms of patient mortality. Even if there are no mortality data available that can be compared with the patient population being investigated here, it becomes apparent that the cardiac mortality rate of just one death in 114 treatment years in a patient group with an initial average age of 60 years and a high risk for CVD is unexpectedly low.

Our study confirmed the safety of LA treatment, as it has been documented in more than 2,500,000 treatments worldwide. This is reflected by the total rate of only 3.3 % of unexpected adverse events, vascular access problems, and technical problems, and a completion rate of 99.5 % of all treatments.

Conclusions {#Sec9}
===========

LA treatment of patients with a high risk for CVD due to LDL- and/or Lp(a)-HLP is effective, safe, and well tolerated. The number of cardiovascular events, at least during a 6-year period, was lowered by 80 %, which is a significant clinical benefit for these high-risk patients. Epidemiological research and prospective studies comparing LA and new Lp(a)-lowering medications might provide further insight into the role of Lp(a) in cardiovascular diseases.
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